|
US7037922B1
(en)
|
2000-03-10 |
2006-05-02 |
Neurogen Corporation |
Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
|
|
JP2002540203A
(ja)
|
1999-03-29 |
2002-11-26 |
ニューロゲン コーポレイション |
Ｎｋ−３および／またはｇａｂａ（ａ）受容体リガンドとしての４−置換キノリン誘導体
|
|
DE60022508T2
(de)
|
1999-06-14 |
2006-06-08 |
Eli Lilly And Co., Indianapolis |
Inhibitoren von serin proteasen
|
|
US6794393B1
(en)
|
1999-10-19 |
2004-09-21 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
HRP20020349A2
(en)
|
1999-10-19 |
2004-02-29 |
Merck & Co Inc |
Tyrosine kinase inhibitors
|
|
US6313138B1
(en)
|
2000-02-25 |
2001-11-06 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
US6420382B2
(en)
|
2000-02-25 |
2002-07-16 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
US6521618B2
(en)
|
2000-03-28 |
2003-02-18 |
Wyeth |
3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
|
|
AU2002226877B2
(en)
|
2000-10-17 |
2006-01-12 |
Merck & Co., Inc. |
Orally active salts with tyrosine kinase activity
|
|
GB0028964D0
(en)
*
|
2000-11-28 |
2001-01-10 |
Smithkline Beecham Spa |
Novel compounds
|
|
AU2002361577A1
(en)
|
2001-10-30 |
2003-05-12 |
Merck And Co., Inc. |
Tyrosine kinase inhibitors
|
|
EP1541149A1
(en)
*
|
2002-06-26 |
2005-06-15 |
Kyowa Hakko Kogyo Co., Ltd. |
Phosphodiesterase inhibitor
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
SG168407A1
(en)
|
2003-01-28 |
2011-02-28 |
Ironwood Pharmaceuticals Inc |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
RU2229475C1
(ru)
*
|
2003-03-06 |
2004-05-27 |
ООО "Исследовательский институт химического разнообразия |
6-сульфамоилхинолин-4-карбоновые кислоты, их производные и комбинаторная библиотека
|
|
TW200804288A
(en)
*
|
2005-12-12 |
2008-01-16 |
Astrazeneca Ab |
Alkylsulphonamide quinolines
|
|
EP2527360B1
(en)
|
2007-06-04 |
2015-10-28 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
US20090118135A1
(en)
*
|
2007-06-08 |
2009-05-07 |
The Burnham Institute |
Methods and compounds for regulating apoptosis
|
|
EP2810951B1
(en)
|
2008-06-04 |
2017-03-15 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
EP3241839B1
(en)
|
2008-07-16 |
2019-09-04 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
|
WO2018129556A1
(en)
|
2017-01-09 |
2018-07-12 |
Ardelyx, Inc. |
Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
SI2384318T1
(en)
|
2008-12-31 |
2018-03-30 |
Ardelyx, Inc. |
MEASURES AND PROCEDURES FOR THE INHIBITION OF ANTIPORT INHIBITED BY NHE IN THE TREATMENT OF DISEASES RELATED TO STRENGTH OF FLAMMABILITY OR TRADEMARITY WITH SOLO, AND THE EMISSION OF GASTROINTESTINAL TREATMENT
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
US10376481B2
(en)
|
2012-08-21 |
2019-08-13 |
Ardelyx, Inc. |
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
MX366293B
(es)
|
2012-08-21 |
2019-07-04 |
Ardelyx Inc |
Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
|
|
CA2905435A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
|
CA2905438A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
|
LT2983667T
(lt)
|
2013-04-12 |
2019-07-10 |
Ardelyx, Inc. |
Nhe3 rišantys junginiai ir fosfato pernešimo slopinimo būdai
|
|
CA2909752A1
(en)
|
2013-04-19 |
2014-10-23 |
Astrazeneca Ab |
A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)
|
|
SI3004138T1
(sl)
|
2013-06-05 |
2024-07-31 |
Bausch Health Ireland Limited |
Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
|
|
ES2726927T3
(es)
*
|
2014-07-08 |
2019-10-10 |
Dow Agrosciences Llc |
Proceso para la preparación de ácidos 3-hidroxipicolínicos
|
|
WO2017072629A1
(en)
|
2015-10-29 |
2017-05-04 |
Cadila Healthcare Limited |
Pharmaceutical combination of nk3 receptor antagonist and biguanides
|
|
EA201991676A1
(ru)
|
2017-01-09 |
2020-01-30 |
Арделикс, Инк. |
Ингибиторы nhe-опосредованного антипорта
|
|
CA3049678A1
(en)
|
2017-01-09 |
2018-07-12 |
Ardelyx, Inc. |
Compounds useful for treating gastrointestinal tract disorders
|
|
JPWO2020101017A1
(ja)
*
|
2018-11-15 |
2021-09-30 |
国立大学法人九州大学 |
Ｉｌ−３１介在性疾患の予防又は治療剤及び医薬組成物
|